Chimeric antigen receptor (CAR) T-cell therapies marry advances in cellular engineering with personalized medicine to provide patient-specific, targeted cancer treatments. Though current CAR T-cell therapies successfully target blood cell cancers, treating solid tumors has proven to be more challenging. Solid-tumor CAR designs must overcome several challenges, including tumor microenvironment barriers...